Kyeong Han Kim1,2, Ho-Yeon Go3, Ju Ah Lee4, Jiae Choi5, Sunju Park6, Myeong Soo Lee5, Seong-Gyu Ko2. 1. 1 Korea Health Promotion Foundation , Toegye-ro, Korea. 2. 2 Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University , Seoul, Republic of Korea. 3. 3 Internal Medicine College of Korean Medicine, Semyung University , Chungju, Republic of Korea. 4. 4 KM Fundamental Research Division, Korea Institute of Oriental Medicine , Daejeon, Republic of Korea. 5. 5 Clinical Research Division, Korea Institute of Oriental Medicine , Daejeon, Republic of Korea. 6. 6 Department of Preventive Medicine, College of Korean Medicine, Daejeon University , Daejeon, Republic of Korea.
Abstract
OBJECTIVES: The aim of this study was to evaluate the safety and the effect of dangguijagyag-san (DJS) on mild cognitive impairment (MCI). METHODS: This study examined the administration of DJS ([Formula: see text]; angelica and peony formula) and was conducted at Uijeongbu Health Center in Gyeonggi-do, Korea, in 2013. Ninety-five of 118 patients diagnosed with MCI were followed up for 1 year after the study ended, and their medical records were analyzed. RESULTS: The patients included 36 men (37.9%) and 59 women (62.1%). When the results from before the study began were compared with the results 1 year after the study ended, the overall average score according to the Korean-Montreal Cognitive Assessment (K-MOCA) showed a statistically significant increase, from 15.46 ± 5.30 to 18.54 ± 5.11, respectively. Both male and female patients recorded a significant increase in K-MOCA scores for all sections, including the visuospatial/executive section, the naming section, the attention section, the language section, the abstraction section, the delayed recall section, and the orientation section. Scores assessed by the Mini-Mental State Examination for Dementia Screening (MMSE-DS) showed a statistically significant increase, from 21.84 ± 3.59 before the study to 24.43 ± 3.13 after the study, but decreased slightly to 23.04 ± 3.36 at the 1-year follow-up. However, MMSE-DS scores measured before the study began increased significantly when compared with scores measured 1 year after the study ended. CONCLUSIONS: DGJYS improved the cognitive skills of patients diagnosed with MCI, and no adverse effects were observed. In the future, the efficacy of DGJYS must be objectively verified by using a randomized controlled trial.
RCT Entities:
OBJECTIVES: The aim of this study was to evaluate the safety and the effect of dangguijagyag-san (DJS) on mild cognitive impairment (MCI). METHODS: This study examined the administration of DJS ([Formula: see text]; angelica and peony formula) and was conducted at Uijeongbu Health Center in Gyeonggi-do, Korea, in 2013. Ninety-five of 118 patients diagnosed with MCI were followed up for 1 year after the study ended, and their medical records were analyzed. RESULTS: The patients included 36 men (37.9%) and 59 women (62.1%). When the results from before the study began were compared with the results 1 year after the study ended, the overall average score according to the Korean-Montreal Cognitive Assessment (K-MOCA) showed a statistically significant increase, from 15.46 ± 5.30 to 18.54 ± 5.11, respectively. Both male and female patients recorded a significant increase in K-MOCA scores for all sections, including the visuospatial/executive section, the naming section, the attention section, the language section, the abstraction section, the delayed recall section, and the orientation section. Scores assessed by the Mini-Mental State Examination for Dementia Screening (MMSE-DS) showed a statistically significant increase, from 21.84 ± 3.59 before the study to 24.43 ± 3.13 after the study, but decreased slightly to 23.04 ± 3.36 at the 1-year follow-up. However, MMSE-DS scores measured before the study began increased significantly when compared with scores measured 1 year after the study ended. CONCLUSIONS: DGJYS improved the cognitive skills of patients diagnosed with MCI, and no adverse effects were observed. In the future, the efficacy of DGJYS must be objectively verified by using a randomized controlled trial.